Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 21 min ago
Peer-reviewedCC BY-NC-NDTranslational Lung Cancer Research

Impact of different TP53 mutation subtypes on response and outcome in advanced lung adenocarcinoma receiving first-line immunotherapy or chemo-immunotherapy

Read full textPDFCite

Related

  1. CT-based prediction of EGFR mutation subtypes and TP53 co-mutation status in lung adenocarcinoma
    Haixian Liu, Zhi Li, Yingqi Zhang +8
    Frontiers in Molecular BiosciencesPeer-reviewedCC BY 4.0Full textMedical imaging & radiologyPMC
  2. Multi-Platform Transcriptomic Classification of LUAD Driver Mutation Subtypes via Heterogeneous Ensemble Learning
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Identification of CRF-related molecular subtypes and a prognostic CRRS model in glioma: insights into immunotherapy response prediction and candidate biomarkers
    Jihao Xue, Jianguo Xu, Qijia Yin +1
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Human geneticsCrossref
  4. 994 Predicting immune-related inflammatory arthritis in patients with cancer receiving immunotherapy
    Namrata Singh, Pankti Reid, Wooyoung Kim +3
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYOncologyDOAJ
  5. Hidden in Plain Sight: Gastric Adenocarcinoma in Endoscopically Normal Mucosa in a CDH1 Mutation Carrier
    Seth Mills, Abinash Subedi
    ACG case reports journalPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{anon2026impact,
  title = {{Impact of different TP53 mutation subtypes on response and outcome in advanced lung adenocarcinoma receiving first-line immunotherapy or chemo-immunotherapy}},
  journal = {Translational Lung Cancer Research},
  year = {2026},
  month = aug,
  url = {https://europepmc.org/article/PMC/PMC13657863},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Impact of different TP53 mutation subtypes on response and outcome in advanced lung adenocarcinoma receiving first-line immunotherapy or chemo-immunotherapy
PY  - 2026
DA  - 2026/08/28
JO  - Translational Lung Cancer Research
UR  - https://europepmc.org/article/PMC/PMC13657863
SN  - 2218-6751
ER  -